Phase I & II clinical trial expertise

With our extensive expertise in developing and implementing adaptive protocols for Phase I and II trials, we excel in optimising sponsors' studies, ensuring maximum returns while prioritising the safety of our participants

Benefits of using our Phase I & II clinical trials

At Richmond Pharmacology, we prioritise adding value by gathering extensive and highly relevant data within a limited budget. Our focus is on collecting and analysing essential data that directly aligns with the trial objectives.

To ensure efficiency and participant safety, we carefully limit assessments and exposure to only what is necessary and essential for the study.

By tailoring our adaptive limits and implementing robust control mechanisms for each protocol, we effectively manage potential risks and optimise the overall trial process.

Maximising efficiency is at the core of our approach. We employ umbrella protocols that integrate various elements such as ethnic comparison, intensive cardiac assessments, and other biomarkers into a combined framework. This approach not only streamlines the data collection process but also mitigates potential risks associated with subsequent stages of drug development.

By implementing umbrella protocols, we can leverage the data collected across multiple aspects of the study, eliminating redundancy and reducing overall costs. This integrated approach allows us to efficiently assess different parameters and gather comprehensive data while maintaining participant safety as our top priority.

The inclusion of ethnic comparison elements in our umbrella protocols ensures that the trial results can be generalised across diverse populations, providing valuable insights into the safety of the investigational treatments for different ethnic groups.

Additionally, our focus on intensive cardiac assessments and other relevant biomarkers within the umbrella protocol allows for a thorough evaluation of potential cardiovascular risks associated with the investigational drug. This comprehensive approach not only enhances patient safety but also provides valuable data for informed decision making during subsequent stages of drug development.

We maximise return on our sponsors' trials

Using adaptive design to support rational “no-go” or “where to go next” decisions, an entire early phase programme from First-In-Human to Proof of Concept can be performed in one trial protocol, in one trial centre.

Get in touch today

Why Richmond Pharmacology?


Systematic and logical protocols

We adapt the trial design whilst maintaining the validity of the data and integrity of the trial.

Read more +

Competent and fast decisions

We guarantee rapid progression of your trial.

Read more +

Rapid approval

We have an excellent track record for starting studies on time and effectively managing ethics and regulatory submissions.

Read more +

Time efficient

Fast and efficient adaptive protocol development using a transparent and systematic approach.

Read more +

Our adaptive protocols enable immediate implementation of adaptive changes leading to early decision making and efficient use of essential data outputs.

Latest news

Single-dose gene silencing cure for fatal heart disease comes one step closer

March 20, 2024
Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis
Read more

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more


ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event